Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone415-482-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.19 billion
Profitability
Miscellaneous
Employees618
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) posted its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.17. The biopharmaceutical company had revenue of $23.32 million for the quarter, compared to analyst estimates of $26.65 million. Nektar Therapeutics had a negative return on equity of 25.25% and a negative net margin of 354.90%. Nektar Therapeutics's revenue for the quarter was down 97.9% compared to the same quarter last year. During the same period last year, the company earned $5.33 earnings per share. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
13 equities research analysts have issued 12-month price targets for Nektar Therapeutics' stock. Their forecasts range from $21.00 to $100.00. On average, they expect Nektar Therapeutics' share price to reach $50.4167 in the next year. This suggests a possible upside of 196.9% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.
What is the consensus analysts' recommendation for Nektar Therapeutics?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our new 12-month, $24, vs. our prior $47 target on shares of Nektar is based on a 12-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.62, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027." (8/13/2019)
- 2. According to Zacks Investment Research, "Nektar has a promising pipeline with several candidates and regulatory updates lined up for the next several quarters. Moreover, regular partnerships have enhanced the company’s financial position. Nektar is poised to receive sales milestone payments plus royalties for Movantik, Adynovate and Neulasta, under license agreements with AstraZeneca, Takeda and Amgen, respectively. Its recent co-development deals with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 are encouraging. The deals provide revenues and reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company’s results in the future. Loss estimates have narrowed ahead of the Q2 results. The company has a positive record of earnings surprises in the recent quarters." (7/31/2019)
- 3. William Blair analysts commented, "We traveled with LeMaitre management last week as the company met with Barrington clients in Richmond, VA. This marked the second time in a month that we have spent time on the road with members of this management team and the messaging remains consistent and long-term bullish despite some short-term challenges." (6/14/2019)
- 4. Mizuho analysts commented, "We expect these events to be important drivers for NKTR shares as we continue to believe that a majority of the company’s value lies in NKTR-214." (3/1/2019)
Has Nektar Therapeutics been receiving favorable news coverage?
News stories about NKTR stock have been trending positive on Thursday, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Nektar Therapeutics earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the company's share price in the near future. View News Stories for Nektar Therapeutics.
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include Genmab A/S (GNMSF), Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), SAGE Therapeutics (SAGE), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Teva Pharmaceutical Industries (TEVA), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Sarepta Therapeutics (SRPT), Beigene (BGNE) and Perrigo (PRGO).
What other stocks do shareholders of Nektar Therapeutics own?
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
- Mr. John Nicholson, Sr. VP & COO (Age 67)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
- Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Invesco Ltd. (13.39%), Primecap Management Co. CA (10.89%), Vanguard Group Inc. (10.62%), BlackRock Inc. (7.61%), First Trust Advisors LP (1.72%) and Camber Capital Management LP (1.43%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which major investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Morgan Stanley, Primecap Management Co. CA, Retirement Systems of Alabama, California Public Employees Retirement System, Wells Fargo & Company MN, Cormorant Asset Management LP and SG Americas Securities LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which major investors are buying Nektar Therapeutics stock?
NKTR stock was bought by a variety of institutional investors in the last quarter, including Invesco Ltd., Nuveen Asset Management LLC, First Trust Advisors LP, BlackRock Inc., Camber Capital Management LP, Vanguard Group Inc., Acadian Asset Management LLC and Pictet Asset Management Ltd.. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $16.98.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $2.98 billion and generates $1.19 billion in revenue each year. The biopharmaceutical company earns $681.31 million in net income (profit) each year or $3.78 on an earnings per share basis. Nektar Therapeutics employs 618 workers across the globe.View Additional Information About Nektar Therapeutics.
What is Nektar Therapeutics' official website?
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
